title: Medicine. (De)personalized medicine.
authors.affiliation: Clinical Evaluation Sciences, GlaxoSmithKline, King of Prussia, PA 19406, USA.
authors.forename: Ralph I
authors.initials: RI
authors.lastname: Horwitz
authors.forename: Mark R
authors.initials: MR
authors.lastname: Cullen
authors.forename: Jill
authors.initials: J
authors.lastname: Abell
authors.forename: Jennifer B
authors.initials: JB
authors.lastname: Christian
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D023281:Genomics / Q000379:methods*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D009203:Myocardial Infarction / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use; D057285:Precision Medicine / Q000379:methods* / Q000639:trends*; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate